stockrow
Saturday 7 November 2026
Export OABI’s income statement to Excel — free account
OmniAb, Inc.
OABI Healthcare Biotechnology
OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024.
- Revenue
- +78.3%
- EPS
- +14.3%
- Free cash flow
- +206.3%
Quarter to September 2026, against a year earlier
5.02
0.19
+3.93%
Follow OABI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 35 | 59 | 34 | 26 | 19 | 40 | (14.4%) | 35 | 44 | 63 | +50.4% | |
| Gross margin, % | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 98.38 | 97.65 | (1.6) pt | ||||||
| EBT | — | — | — | — | — | (34) | (26) | (64) | (71) | (66) | (44) | +17.9% | ||||||
| EBT margin, % | — | — | — | — | — | (98.85) | (44.11) | (188.39) | (270.59) | (355.16) | (109.12) | (256.3) pt | ||||||
| Net income | — | 0 | — | — | — | (27) | (22) | (51) | (62) | (65) | (43) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.42 | 0.69 | 0.34 | 0.26 | 0.16 | 0.31 | (20.9%) | |||||
| Earnings | — | — | — | — | — | (0.33) | (0.26) | (0.51) | (0.61) | (0.57) | (0.34) | +14.9% | ||||||
| Cash flow | — | — | — | — | — | (0.07) | (0.04) | 0.02 | (0.39) | (0.32) | 0.02 | +47.0% | ||||||
| Capex | — | — | — | — | — | (0.05) | (0.20) | (0.02) | (0.02) | 0.02 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | (0.12) | (0.24) | 0.01 | (0.41) | (0.30) | 0.02 | +26.2% | ||||||
| Book value | — | — | — | — | — | 2.84 | 4.00 | 3.16 | 2.81 | 2.35 | 1.93 | (4.6%) | ||||||
| Shares, m | — | — | — | — | — | 83 | 85 | 100 | 102 | 114 | 125 | +8.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 0.00 | 5.01 | 18.24 | 13.73 | 11.26 | 16.14 | 9.6 | ||||||
| P/B | — | — | — | — | — | 3.53 | 0.87 | 1.98 | 1.26 | 0.79 | 2.61 | 1.7 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | 3.52 | 15.69 | 11.48 | 8.37 | 14.54 | 7.8 | ||||||
| EV/FCF | — | — | — | — | — | (145.62) | (10.01) | 762.50 | (7.29) | (4.59) | 245.74 | 119.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (6) | (4) | 2 | (40) | (36) | 3 | +59.2% | |||||
| Capex | — | — | — | — | — | (4) | (17) | (2) | (2) | 2 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | — | (10) | (21) | 1 | (42) | (34) | 2 | +36.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 2 | 99 | 72 | 53 | 49 | 54 | +123.6% | |||||
| Net debt | — | — | — | — | — | 0 | (88) | (87) | (59) | (54) | (64) | +310.6% | ||||||
| Shareholders’ equity | — | — | — | — | — | 234 | 341 | 315 | 288 | 267 | 249 | +3.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (17.76) | (6.16) | (12.71) | (17.70) | (20.68) | (14.48) | (2.9) pt | |||||
| ROIC | — | — | — | — | — | (9.51) | (6.58) | (19.06) | (20.41) | (20.24) | (15.75) | (10.7) pt | ||||||
| ROE | — | — | — | — | — | 0.00 | (7.76) | (15.43) | (20.60) | (23.36) | (16.51) | (23.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 0 | 95 | 106 | 114 | 89 | — | n/m | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.62 | 0.32 | 0.23 | 0.21 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026
OmniAb, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ARDX Ardelyx, Inc. | $751.6M | — (loss-making) | — (loss-making) | +15.70% (above 0%: growing) | n/m | +938.76% (above 0%: growing) | 96.44% | 3.15% | Compare |
| LXRX Lexicon Pharmaceuticals, Inc. | $716.4M | — (loss-making) | — (loss-making) | −20.67% (below 0%: shrinking) | n/m | +66.10% (above 0%: growing) | 99.30% | (128.84%) | Compare |
| OABI OmniAb, Inc. | $704.5M | — (loss-making) | — (loss-making) | +78.34% (above 0%: growing) | n/m | +206.33% (above 0%: growing) | 92.26% | (409.92%) | |
| SANA Sana Biotechnology, Inc. | $700.5M | — (loss-making) | — | — | n/m | −5.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CGEM Cullinan Therapeutics, Inc. | $695.0M | — (loss-making) | 4.8× | — | n/m | +33.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ATTO Attovia Therapeutics, Inc. | $684.8M | — | — | — | n/m | — | 100.00% | (4,845.11%) | Compare |
| DNA Ginkgo Bioworks Holdings, Inc. | $670.7M | — (loss-making) | — (loss-making) | −59.37% (below 0%: shrinking) | n/m | −16.38% (below 0%: shrinking) | 91.47% | (290.47%) | Compare |
| SLDB Solid Biosciences Inc. | $662.7M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −39.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $689.9M | — | — | −40.02% | — | −5.46% | 93.96% | 0.00% |
Pay and ownership Proxy statement filed 29 April 2026
Ownership
Directors and executive officers, together
9.80%
Entities affiliated with Avista Capital Partners
17.40%
Entities affiliated with Whitefort Capital Management, LP
9.80%
Entities affiliated with Ash X LP
9.50%
Entities affiliated with BlackRock, Inc.
5.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement